The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer

Summary In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2014-05, Vol.45 (5), p.926-934
Hauptverfasser: Ao, Ming-Hui, MS, Zhang, Hui, PhD, Sakowski, Lynne, MS, Sharma, Rajni, PhD, Illei, Peter B., MD, Gabrielson, Edward, MD, Askin, Frederic, MD, Li, Qing Kay, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 934
container_issue 5
container_start_page 926
container_title Human pathology
container_volume 45
creator Ao, Ming-Hui, MS
Zhang, Hui, PhD
Sakowski, Lynne, MS
Sharma, Rajni, PhD
Illei, Peter B., MD
Gabrielson, Edward, MD
Askin, Frederic, MD
Li, Qing Kay, MD, PhD
description Summary In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non–small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.
doi_str_mv 10.1016/j.humpath.2014.01.005
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4178947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S004681771400029X</els_id><sourcerecordid>3281565261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-aa70e52cd2cabf0ea021787404b6eee2fb3e6bc7c88d9e9d4e7635a6b45186c03</originalsourceid><addsrcrecordid>eNpdUk1v1DAQjRCILoWfALLEpUhNGDvO1wWpqiggVeLAInGzHGfS9daxg52stDdO_AH-Ib8Ehy5b4GLLmvfezPObJHlOIaNAy9fbbDMPo5w2GQPKM6AZQPEgWdEiZ2mdN-xhsgLgZVrTqjpJnoSwBaC04MXj5ITxipe0qVbJ9_UGyTxpo6c9cT2RxLodGjJ5PRokg_S36MmZckOrrZy0swtqvb6i58TKMWhLLs6JtB0ZObwi8TlFwTC3ysgQdK_VkWSd_fntRxikMURhPMxsb4iSVqF_mjzqpQn47HCfJp-v3q4v36fXH999uLy4TlVRwpRKWQEWTHVMybYHlMBoVVcceFsiIuvbHMtWVaquuwabjmNV5oUsW17QulSQnyZv7nTHuR2wU2gnL40YvY5O98JJLf6tWL0RN24neOzT8CoKnB0EvPs6Y5jEoMPiRlp0cxA0NmKc53SBvvwPunWzt9HebxRlFAoaUcUdSnkXgsf-OAwFsSQttuKQtFiSFkBFTDryXvzt5Mj6E-29VYz_udPohTLaxjzMLe4x3M8iAhMgPi3LsuwK5QDAmi_5L1bEvgo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1518121051</pqid></control><display><type>article</type><title>The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ao, Ming-Hui, MS ; Zhang, Hui, PhD ; Sakowski, Lynne, MS ; Sharma, Rajni, PhD ; Illei, Peter B., MD ; Gabrielson, Edward, MD ; Askin, Frederic, MD ; Li, Qing Kay, MD, PhD</creator><creatorcontrib>Ao, Ming-Hui, MS ; Zhang, Hui, PhD ; Sakowski, Lynne, MS ; Sharma, Rajni, PhD ; Illei, Peter B., MD ; Gabrielson, Edward, MD ; Askin, Frederic, MD ; Li, Qing Kay, MD, PhD</creatorcontrib><description>Summary In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non–small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2014.01.005</identifier><identifier>PMID: 24746197</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Adenocarcinoma - classification ; Adenocarcinoma - pathology ; Adenocarcinoma - secondary ; Adenocarcinoma of Lung ; Aged ; Aged, 80 and over ; Aspartic Acid Endopeptidases - analysis ; Biopsy ; Carcinoma, Non-Small-Cell Lung - classification ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Squamous Cell - classification ; Carcinoma, Squamous Cell - pathology ; DNA-Binding Proteins - analysis ; Female ; Humans ; Immunodominant Epitopes - analysis ; Lung cancer ; Lung Neoplasms - classification ; Lung Neoplasms - pathology ; Lung Neoplasms - secondary ; Male ; Middle Aged ; Mutation ; Pathology ; Peptide Fragments - analysis ; Sensitivity and Specificity ; Studies ; Transcription Factors ; Working conditions</subject><ispartof>Human pathology, 2014-05, Vol.45 (5), p.926-934</ispartof><rights>Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited May 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-aa70e52cd2cabf0ea021787404b6eee2fb3e6bc7c88d9e9d4e7635a6b45186c03</citedby><cites>FETCH-LOGICAL-c560t-aa70e52cd2cabf0ea021787404b6eee2fb3e6bc7c88d9e9d4e7635a6b45186c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24746197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ao, Ming-Hui, MS</creatorcontrib><creatorcontrib>Zhang, Hui, PhD</creatorcontrib><creatorcontrib>Sakowski, Lynne, MS</creatorcontrib><creatorcontrib>Sharma, Rajni, PhD</creatorcontrib><creatorcontrib>Illei, Peter B., MD</creatorcontrib><creatorcontrib>Gabrielson, Edward, MD</creatorcontrib><creatorcontrib>Askin, Frederic, MD</creatorcontrib><creatorcontrib>Li, Qing Kay, MD, PhD</creatorcontrib><title>The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Summary In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non–small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.</description><subject>Adenocarcinoma - classification</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma of Lung</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aspartic Acid Endopeptidases - analysis</subject><subject>Biopsy</subject><subject>Carcinoma, Non-Small-Cell Lung - classification</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Squamous Cell - classification</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>DNA-Binding Proteins - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Immunodominant Epitopes - analysis</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - classification</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - secondary</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Pathology</subject><subject>Peptide Fragments - analysis</subject><subject>Sensitivity and Specificity</subject><subject>Studies</subject><subject>Transcription Factors</subject><subject>Working conditions</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUk1v1DAQjRCILoWfALLEpUhNGDvO1wWpqiggVeLAInGzHGfS9daxg52stDdO_AH-Ib8Ehy5b4GLLmvfezPObJHlOIaNAy9fbbDMPo5w2GQPKM6AZQPEgWdEiZ2mdN-xhsgLgZVrTqjpJnoSwBaC04MXj5ITxipe0qVbJ9_UGyTxpo6c9cT2RxLodGjJ5PRokg_S36MmZckOrrZy0swtqvb6i58TKMWhLLs6JtB0ZObwi8TlFwTC3ysgQdK_VkWSd_fntRxikMURhPMxsb4iSVqF_mjzqpQn47HCfJp-v3q4v36fXH999uLy4TlVRwpRKWQEWTHVMybYHlMBoVVcceFsiIuvbHMtWVaquuwabjmNV5oUsW17QulSQnyZv7nTHuR2wU2gnL40YvY5O98JJLf6tWL0RN24neOzT8CoKnB0EvPs6Y5jEoMPiRlp0cxA0NmKc53SBvvwPunWzt9HebxRlFAoaUcUdSnkXgsf-OAwFsSQttuKQtFiSFkBFTDryXvzt5Mj6E-29VYz_udPohTLaxjzMLe4x3M8iAhMgPi3LsuwK5QDAmi_5L1bEvgo</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Ao, Ming-Hui, MS</creator><creator>Zhang, Hui, PhD</creator><creator>Sakowski, Lynne, MS</creator><creator>Sharma, Rajni, PhD</creator><creator>Illei, Peter B., MD</creator><creator>Gabrielson, Edward, MD</creator><creator>Askin, Frederic, MD</creator><creator>Li, Qing Kay, MD, PhD</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140501</creationdate><title>The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer</title><author>Ao, Ming-Hui, MS ; Zhang, Hui, PhD ; Sakowski, Lynne, MS ; Sharma, Rajni, PhD ; Illei, Peter B., MD ; Gabrielson, Edward, MD ; Askin, Frederic, MD ; Li, Qing Kay, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-aa70e52cd2cabf0ea021787404b6eee2fb3e6bc7c88d9e9d4e7635a6b45186c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - classification</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma of Lung</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aspartic Acid Endopeptidases - analysis</topic><topic>Biopsy</topic><topic>Carcinoma, Non-Small-Cell Lung - classification</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Squamous Cell - classification</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>DNA-Binding Proteins - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Immunodominant Epitopes - analysis</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - classification</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - secondary</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Pathology</topic><topic>Peptide Fragments - analysis</topic><topic>Sensitivity and Specificity</topic><topic>Studies</topic><topic>Transcription Factors</topic><topic>Working conditions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ao, Ming-Hui, MS</creatorcontrib><creatorcontrib>Zhang, Hui, PhD</creatorcontrib><creatorcontrib>Sakowski, Lynne, MS</creatorcontrib><creatorcontrib>Sharma, Rajni, PhD</creatorcontrib><creatorcontrib>Illei, Peter B., MD</creatorcontrib><creatorcontrib>Gabrielson, Edward, MD</creatorcontrib><creatorcontrib>Askin, Frederic, MD</creatorcontrib><creatorcontrib>Li, Qing Kay, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ao, Ming-Hui, MS</au><au>Zhang, Hui, PhD</au><au>Sakowski, Lynne, MS</au><au>Sharma, Rajni, PhD</au><au>Illei, Peter B., MD</au><au>Gabrielson, Edward, MD</au><au>Askin, Frederic, MD</au><au>Li, Qing Kay, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>45</volume><issue>5</issue><spage>926</spage><epage>934</epage><pages>926-934</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Summary In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non–small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>24746197</pmid><doi>10.1016/j.humpath.2014.01.005</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2014-05, Vol.45 (5), p.926-934
issn 0046-8177
1532-8392
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4178947
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adenocarcinoma - classification
Adenocarcinoma - pathology
Adenocarcinoma - secondary
Adenocarcinoma of Lung
Aged
Aged, 80 and over
Aspartic Acid Endopeptidases - analysis
Biopsy
Carcinoma, Non-Small-Cell Lung - classification
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Squamous Cell - classification
Carcinoma, Squamous Cell - pathology
DNA-Binding Proteins - analysis
Female
Humans
Immunodominant Epitopes - analysis
Lung cancer
Lung Neoplasms - classification
Lung Neoplasms - pathology
Lung Neoplasms - secondary
Male
Middle Aged
Mutation
Pathology
Peptide Fragments - analysis
Sensitivity and Specificity
Studies
Transcription Factors
Working conditions
title The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20utility%20of%20a%20novel%20triple%20marker%20(combination%20of%20TTF1,%20napsin%20A,%20and%20p40)%20in%20the%20subclassification%20of%20non%E2%80%93small%20cell%20lung%20cancer&rft.jtitle=Human%20pathology&rft.au=Ao,%20Ming-Hui,%20MS&rft.date=2014-05-01&rft.volume=45&rft.issue=5&rft.spage=926&rft.epage=934&rft.pages=926-934&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2014.01.005&rft_dat=%3Cproquest_pubme%3E3281565261%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1518121051&rft_id=info:pmid/24746197&rft_els_id=1_s2_0_S004681771400029X&rfr_iscdi=true